CLSA Wire

Biosimilar Substitution Legislation — SB 671 (Hill)
Facebook
Twitter
LinkedIn

May 21, 2015

Two years ago, CLSA was heavily engaged in passage of legislation enabling biosimilars substitution with patient protections. Although the bill passed out of the legislature, it ended up being vetoed by the Governor, who stated that that the issue was not ripe since the FDA had not approved a biosimilar.

This year’s legislation permits a pharmacist filling a prescription for a biological product to select an alternative, interchangeable biological product if the prescriber does not specifically indicate “Do not substitute” and requires the pharmacist to communicate to the prescriber if a substitution is made. The legislation has now passed out of the Senate Business and Professions Committee, the Senate Health Committee and the Senate Appropriations Committee and heads to the floor for passage out of the Senate.